)
Steffen Dickopf
Senior Director Immuno-Oncology,
Veraxa
Steffen Dickopf is Senior Director Immuno-Oncology at VERAXA Biotech, a clinical-stage company advancing next-generation antibody-based cancer therapies. VERAXA leverages its proprietary BiTAC platform to develop bispecific T-cell engagers and ADCs designed for selective tumor activation, with the goal of improving efficacy and safety. Prior to joining VERAXA, Steffen held positions of increasing responsibility in antibody discovery and Immuno-Oncology at Roche pRED and MorphoSys. He earned his PhD from LMU Munich.
Sessions